GE HealthCare Technologies (GEHC) Business & Investor Dossier

GE HealthCare makes money through four business segments: Imaging (MRI scanners, CT scanners, X-ray systems, molecular imaging/PET-CT -- the largest segment); Ultrasound (diagnostic and point-of-care ultrasound devices for cardiology, obstetrics, radiology, and general imaging); Patient Care Solutions (monitoring systems, anesthesia delivery, respiratory care equipment for hospitals and ICUs); and Pharmaceutical Diagnostics (contrast agents injected into patients before imaging to improve the visibility of tissues and structures on scans -- iodinated contrast for CT, gadolinium-based contrast for MRI, tracers for nuclear medicine/PET). Revenue comes from equipment sales, service contracts (maintenance, software upgrades, parts for installed systems), and consumable agents (Pharmaceutical Diagnostics contrast is consumed per scan, generating recurring revenue). The installed base of GE imaging equipment in hospitals globally generates substantial aftermarket services revenue.

GE HealthCare was spun off from General Electric and began trading as an independent public company on January 4, 2023 (NASDAQ: GEHC). The rationale was consistent with GE CEO Larry Culp's strategy of dismantling GE into three focused companies: GE HealthCare (medical technology), GE Aerospace (aviation engines), and GE Vernova (power/energy). As part of GE, the healthcare division's performance was obscured within the conglomerate, and management attention was divided across very different businesses. As a standalone company, GEHC can set its own capital allocation priorities, compensation structures, and strategic focus appropriate for the medical technology industry. For investors, the spinoff creates a pure-play medical imaging company that can be valued and compared against direct peers (Siemens Healthineers, Philips, Hologic, Becton Dickinson). GE retained approximately 20% of GEHC at the time of the spinoff, selling that stake down over time. Culp became Executive Chairman of GEHC while continuing as GE Aerospace CEO, reflecting the importance of the healthcare spinoff to the overall GE transformation story.

The global medical imaging market is dominated by three major players: GE HealthCare, Siemens Healthineers (a subsidiary of Siemens AG that is also separately listed), and Philips Healthcare (a division of Koninklijke Philips N.V.). Together these three hold approximately 70-80% of the global MRI, CT, and ultrasound market. Canon Medical and Fujifilm also compete in certain segments. Competition is primarily on clinical performance (image quality, scan speed, software-driven diagnostic capability), total cost of ownership, installed base relationships, and service network quality. GE HealthCare's competitive strengths include its broad product portfolio (covering all major imaging modalities), its pharmaceutical diagnostics business (which Siemens and Philips largely lack in the same form), its large installed base (which generates service revenue and creates replacement cycle advantages), and its digital and AI platforms (Edison, which applies AI to image analysis to improve diagnostic accuracy and workflow efficiency). The imaging market is relatively consolidated and the three major players have maintained their positions over many years, suggesting high barriers to entry.

GE HealthCare's Pharmaceutical Diagnostics segment makes contrast agents and radiotracer drugs used in medical imaging procedures. Contrast agents are injected or ingested by patients before imaging scans to make certain tissues, blood vessels, or organs more visible to the scanner. Iodinated contrast agents (for CT scans) and gadolinium-based contrast agents (for MRI) are produced in large volumes -- hundreds of millions of doses per year globally -- and are consumed every time a contrast-enhanced scan is performed. This creates a recurring, consumable revenue stream that is less cyclical than equipment sales and does not depend on hospital capital budgets. GE HealthCare's Pharmaceutical Diagnostics business (including brands like Omnipaque for CT and Clariscan for MRI) generates roughly $2.5-3 billion in annual revenue and is a high-margin business with strong market positions. This segment differentiates GEHC from Siemens Healthineers and Philips, which do not have equivalent contrast agent businesses. The segment also includes nuclear medicine tracers for PET scanning (including Vizamyl for amyloid PET imaging used in Alzheimer's diagnosis).

GE HealthCare's main risks include: hospital capital budget cyclicality, as large imaging equipment (MRI, CT) purchases are discretionary capital expenditures for hospitals that get deferred during economic downturns or healthcare funding constraints; China exposure, as China is a large market for imaging equipment where domestic competitors (United Imaging, Mindray) are growing rapidly with government support to displace Western brands; contrast agent supply disruption risk, as the 2021-2022 global iodinated contrast agent shortage (caused by a GE plant shutdown) demonstrated how dependent the healthcare system is on a few suppliers and how a supply disruption harms both patients and GEHC revenue; GE legacy relationship, as GEHC initially relied on GE for certain shared services and must build out independent corporate infrastructure as a standalone company; and reimbursement and regulatory risk, as changes in imaging reimbursement rates by Medicare/Medicaid or private insurers directly affect hospital demand for imaging procedures and therefore for GEHC equipment.